Jian Qiang Li

Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li.

Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li.

Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li.